Analyst Ratings for Bio-Rad Laboratories Inc. Cl A (BIO)

Updated: 2017-07-29

Shares of Bio-Rad Laboratories Inc. Cl A (NYSE:BIO) have received a consensus rating of Buy from Wall Street analysts. About 30 days ago, BIO was issued an average rating of Overweight.

Of the 4 analysts covering the stock, 3 gave it a buy rating, 1 gave an overweight rating, 0 issued a hold rating, 0 gave an underweight rating, and 0 issued a sell rating. Compared to three months ago, there has been an increase of 2 in the number of analysts with a positive outlook on the stock. Meanwhile, the number of analysts pessimistic about the company has increased by 0.

Many analysts weighed in on price targets for BIO. The most optimistic analyst gave a price target of 275, which equates to a potential upside of 16.35 percent. The most pessimistic price target was 245, implying a possible loss of 3.66 percent. Some investors take price targets and stock ratings with a grain of salt, knowing that some analysts can have indirect business with the stocks they cover.

Over the past month, analysts have revised their estimates for this quarter's earnings, with a net average change of 14.42 percent. This can be compared with the average change in earnings estimates over the past 3 months, which is -16.21 percent. On the other hand, earnings estimates for the fiscal year have been revised upwards by 3.5 percent, as compared to a month ago. If we look at the last 90 days instead, we find a net average change of 6.68 percent in FY estimates.

People are often interested in whether analysts were united in the direction of their revisions. 1 analysts have revised their quarterly estimates upwards in the past 30 days, which can be compared to the 0 analysts that decreased their estimates. Also over the last month, 1 analysts increased their estimates for the FY earnings, while 0 analysts made negative revisions to their fiscal year's estimates.

The growth rate of BIO's earnings is estimated by analysts to be 215.57 percent. It's possible to gain additional insight about growth valuation of a company by looking at the PEG ratio. Investors like to see smaller values for the PEG ratio, as that can indicate whether the high price level of a stock is warranted by high growth. People often look for the PEG ratio to be under 1, although it is frequently more appropriate to compare PEG ratios to the company's peers. The PEG ratio of BIO is 1.17.

In the trailing 52-weeks, BIO hit 239.91 at the highest peak, while it's lowest trading point was 143.39. Today's price is 64.84 percent above the 52-week low, and 1.48 percent lower than its 52-week high. BIO has a P/E ratio of 251.45. Investors typically compare the P/E ratio to a company's peers in the industry. The BIO value stock report compares BIO to some of its peers using value stock charts. The stock has a market capitalization of $7.03 billion. BIO will post this quarters earnings in days, on 0000-00-00.